MongoDB Stock Tumbles After Q1 Guidance Miss
MongoDB's shares plunged 23% after announcing weaker-than-expected Q1 forecasts, despite strong Q4 results.
Already have an account? Sign in.
MongoDB's shares plunged 23% after announcing weaker-than-expected Q1 forecasts, despite strong Q4 results.
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
Another major exit follows Noam Shazeer’s move to OpenAI.